首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Use of contraindicated drugs in patients with chronic liver disease: A therapeutic dilemma
【24h】

Use of contraindicated drugs in patients with chronic liver disease: A therapeutic dilemma

机译:慢性肝病患者使用禁忌药物的治疗困境

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: To investigate the prevalence of prescribing of contraindicated drugs or those requiring caution, in hospital inpatients with chronic liver disease. Methods: The medical records and drug charts of adult hospitalized patients, consecutively admitted with clinical documentation and biochemical evidence of chronic liver disease, were studied retrospectively. Comparison was made between the prescription details for each drug and the recommendations for use in patients with liver disease under the approved product information, which indicates drugs that could be hepatotoxic and those that could have markedly altered pharmacokinetics or pharmacodynamics in chronic liver disease. Results: 49 eligible patients with both clinical documentation and confirmatory biochemical evidence of chronic liver disease were identified. Of these, 15 had received at least 1 contraindicated medication during hospitalization, with diazepam being the most common. 31 patients had received at least 1 drug which requires precaution in liver disease, with propranolol being the most common. Conclusion: The use of contraindicated drugs or those requiring caution, occurred frequently in hospital patients with chronic liver disease. This could reflect the somewhat limited evidence base and the perhaps overly cautious nature of the official product information.
机译:目的:探讨在慢性肝病住院患者中开具禁忌药或需要谨慎使用的药物的患病率。方法:回顾性研究了成年住院患者的病历和药物图表,这些患者连续获得了慢性肝病的临床资料和生化证据。在批准的产品信息下,将每种药物的处方详细信息与在肝病患者中使用的建议进行了比较,这表明在慢性肝病中可能具有肝毒性的药物和可能显着改变药代动力学或药效学的药物。结果:确定了49名符合条件的患者,这些患者均具有慢性肝病的临床记录和确证的生化证据。其中,有15名在住院期间至少接受过1种禁忌药物治疗,其中地西epa是最常见的。 31名患者至少接受了1种需要预防肝病的药物,其中普萘洛尔是最常见的药物。结论:慢性肝病住院患者经常使用禁忌药物或需要谨慎使用的药物。这可能反映出有限的证据基础以及官方产品信息的过度谨慎性质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号